Xuanzhu Biopharm Co Ltd

Xuanzhu Biopharmaceutical Co., Ltd. develops, industrializes, and commercializes small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead candidates include KBP-3571 for duodenal ulcer, adult reflux esophagitis, and pylori eradication; XZP-3287, a CDK4/6 inhibitor for HR+/HER2- advanced breast cancer, R+/HER2- locally advanced or metastatic breast cancer, and adjuvant therapy for HR+/HER2- early breast cancer; and XZP-3621 for first-line treatment of ALK-positive advanced non-small-cell lung cancer and post-operative adjuvant therapy for ALK-positive non-small cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate in Phase I; KM602 in Phase I for anti-tumor; XZP-7797, a selective brain-penetrating poly ADP-ribose polymerase 1 inhibitor; XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor; XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a clinical-stage intravenously administered oncolytic immunotherapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, it is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.